These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1810261)

  • 21. Modelling cortical cataractogenesis 21: in diabetic rat lenses taurine supplementation partially reduces damage resulting from osmotic compensation leading to osmolyte loss and antioxidant depletion.
    Mitton KP; Linklater HA; Dzialoszynski T; Sanford SE; Starkey K; Trevithick JR
    Exp Eye Res; 1999 Sep; 69(3):279-89. PubMed ID: 10471336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of polyol pathways in formation of diabetic cataracts].
    Sabasiński K; Andrzejewska-Buczko J
    Klin Oczna; 1997; 99(6):401-4. PubMed ID: 9685789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-cataract Effect of Resveratrol in High-Glucose-Treated Streptozotocin-Induced Diabetic Rats.
    Higashi Y; Higashi K; Mori A; Sakamoto K; Ishii K; Nakahara T
    Biol Pharm Bull; 2018; 41(10):1586-1592. PubMed ID: 30270328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GP-1447, an inhibitor of aldose reductase, prevents the progression of diabetic cataract in rats.
    Kawakubo K; Mori A; Sakamoto K; Nakahara T; Ishii K
    Biol Pharm Bull; 2012; 35(6):866-72. PubMed ID: 22687477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Jones ML; Gunn DE; Geraci LS; Jones JH; Sawicki DR; Sredy J; Jacot JL; Dicioccio AT; Petrova T; Mitschler A; Podjarny AD
    J Med Chem; 2005 May; 48(9):3141-52. PubMed ID: 15857120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Ashizawa N; Yoshida M; Sugiyama Y; Akaike N; Ohbayashi S; Aotsuka T; Abe N; Fukushima K; Matsuura A
    Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential aldose reductase inhibitors: 1,2,4-triazolidine-3,5-diones and 2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione .
    Hall IH; Izydore RA; Simlot R; Wong OT
    Experientia; 1992 Apr; 48(4):383-6. PubMed ID: 1582496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats.
    Ishida H; Mitamura T; Takahashi Y; Hisatomi A; Fukuhara Y; Murato K; Ohara K
    Toxicology; 1997 Dec; 123(3):167-75. PubMed ID: 9355935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diabetic cataract and flavonoids (first results) (author's transl)].
    Leuenberger PM
    Klin Monbl Augenheilkd; 1978 Apr; 172(4):460-2. PubMed ID: 418268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The polyol pathway, sorbinil, and renal dysfunction.
    Beyer-Mears A
    Metabolism; 1986 Apr; 35(4 Suppl 1):46-54. PubMed ID: 3083209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats.
    Reddi AS; Jyothirmayi GN
    J Diabetes Complications; 1993; 7(4):233-40. PubMed ID: 8219366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delaying of cataract through intervention of Hemidesmus indicus in STZ induced diabetic rats.
    Tirumani P; Venu S; Sridhar G; Praveen Kumar M; Rajashekhar AV; Naga Raju T
    Nat Prod Res; 2018 Jun; 32(11):1295-1298. PubMed ID: 28580798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel high resolution in vivo digital imaging system for the evaluation of experimental cataract in diabetic rats.
    Kametaka S; Kasahara T; Ueo M; Takenaka M; Saito M; Sakamoto K; Nakahara T; Ishii K
    J Pharmacol Sci; 2008 Jan; 106(1):144-51. PubMed ID: 18187926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
    McCaleb ML; McKean ML; Hohman TC; Laver N; Robison WG
    Diabetologia; 1991 Oct; 34(10):695-701. PubMed ID: 1959701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling cortical cataractogenesis: 3. In vivo effects of vitamin E on cataractogenesis in diabetic rats.
    Ross WM; Creighton MO; Stewart-DeHaan PJ; Sanwal M; Hirst M; Trevithick JR
    Can J Ophthalmol; 1982 Apr; 17(2):61-6. PubMed ID: 7104839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of diabetes-associated complications by nucleophilic compounds.
    Kumari K; Umar S; Bansal V; Sahib MK
    Diabetes; 1991 Aug; 40(8):1079-84. PubMed ID: 1907249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Some effects of aldose reductase inhibition upon the eyes of long-term streptozotocin-diabetic rats.
    Poulsom R; Boot-Handford RP; Heath H
    Curr Eye Res; 1982-1983; 2(5):351-5. PubMed ID: 6819916
    [No Abstract]   [Full Text] [Related]  

  • 38. Confirmation of lens hydration by Raman spectroscopy.
    Mizuno A; Toshima S; Mori Y
    Exp Eye Res; 1990 Jun; 50(6):647-9. PubMed ID: 2115454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state.
    Nakano I; Tsugawa T; Shinohara R; Watanabe F; Fujita T; Nagata M; Kato T; Himeno Y; Kobayashi T; Fujiwara K; Nagata M; Itoh M; Nagasaka A
    J Diabetes Complications; 2003; 17(6):337-42. PubMed ID: 14583178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of cataract by pyruvate in experimentally diabetic mice.
    Hegde KR; Varma SD
    Mol Cell Biochem; 2005 Jan; 269(1-2):115-20. PubMed ID: 15786723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.